The second virtual meeting of the year for the TREAT-NMD Advisory Committee for Therapeutics (TACT) occurred on September 29th to review a programme in Duchenne muscular dystrophy.
TACT is composed of two main groups: the ‘core committee’, a multidisciplinary team of 10 members who participate in all review meetings, and the ‘extended committee’, a global network of over 150 experts. The core committee, along with specifically chosen experts from the extended committee, will provide guidance on the translational and developmental pathways to the company on their Duchenne programme via a comprehensive report.
Earlier this year, the panel convened in Philadelphia for an in-person meeting where they reviewed four programmes and, in June, a virtual panel gathered to evaluate an application related to LGMD.
Coming up later this year, three more virtual reviews are scheduled.
Applications are also currently open for the Spring 2024 meeting, which is scheduled to take place in Amsterdam from April 19th– 21st. If you are interested in presenting your programme to TACT, please reach out to us at firstname.lastname@example.org for comprehensive application instructions.